Ictal SPECT with intravenous injection in a cubital vein of a perfusion tracer is an established technique to localize the ictal onset zone during presurgical evaluation of refractory focal epilepsy. When seizures last less than 10 seconds, localizing information is often not obtained. Since it takes around 30 seconds before the tracer reaches the brain after intravenous injection, ictal hyperperfusion most likely has already switched to postictal hypoperfusion. In this study, we plan to inject the perfusion tracer in the aorta proximal to the cerebral arteries, which will allow a true ictal injection in patients with seizures of short duration.

Start Date01 May 2016

Sponsor / Collaborator

Universitaire Ziekenhuizen Leuven

100 Clinical Results associated with Technetium Tc-99M Bicisate Kit

100 Translational Medicine associated with Technetium Tc-99M Bicisate Kit

100 Patents (Medical) associated with Technetium Tc-99M Bicisate Kit

188

Literatures (Medical) associated with Technetium Tc-99M Bicisate Kit

01 Jun 2024·Radiological Physics and Technology

Feasibility study of radioactivity estimation of 99mTc and 123I-labeled radiopharmaceuticals using shielded syringes

Article

Author: Yasuno, Narumi ; Nakamura, Yuto

This study investigates the feasibility of estimating the radioactivity of radiopharmaceuticals using shielded syringes. The radioactivities of ^99mTc-MDP, ^99mTc-HMDP, ^99mTc-ECD, ^99mTc-MAG₃, and ¹²³I-IMP were measured using a dose calibrator. Correlation coefficients and regression equations were obtained from the radioactivity in the shielded and unshielded syringes. ^99mTc-MDP was also measured for residual radioactivity after the administration. The correlation coefficients of ^99mTc-MDP, ^99mTc-HMDP, ^99mTc-ECD, ^99mTc-MAG₃, and ¹²³I-IMP were r_s = 0.9998, r_s = 0.9997, r_s = 0.9999, r_s = 0.9998, and r_s = 0.9888, respectively. The regression equations were y = 0.0364x + 0.0913, y = 0.0349x + 0.0273, y = 0.0343x - 0.0018, y = 0.0522x + 0.1215, and y = 0.0383x + 0.0058, respectively. The correlation coefficient for the residual radioactivity of ^99mTc-MDP was r_s = 0.9887 and the regression equation was y = 0.1505x + 0.0853. The radioactivity of ^99mTc- and ¹²³I-labeled radiopharmaceuticals in shielded syringes was accurately measured. It was suggested that the measuring shielded syringes could provide an estimate of the actual radioactivity.

01 Nov 2021·Clinical Nuclear MedicineQ3 · MEDICINE

No Evidence to Favor 99mTc-HMPAO or 99mTc-ECD for Ictal Brain Perfusion SPECT for Identification of the Seizure Onset Zone

Q3 · MEDICINE

Article

Author: Stodieck, Stefan ; Apostolova, Ivayla ; Jaber, Mariam ; Lanz, Michael ; Sauvigny, Thomas ; Voges, Berthold ; Lindenau, Matthias ; Martens, Tobias ; Klutmann, Susanne ; House, Patrick M ; Buchert, Ralph ; Taherpour, Jila

PurposeIctal brain perfusion SPECT with the tracer 99mTc-HMPAO or 99mTc-ECD is widely used for identification of the epileptic seizure onset zone (SOZ) in presurgical evaluation if standard pointers are uncertain or inconsistent. For both tracers, there are theoretical arguments to favor it over the other for this task. The aim of this study was to compare the performance of ictal brain perfusion SPECT between 99mTc-HMPAO and 99mTc-ECD in a rather large patient sample.Patients and MethodsThe study retrospectively included 196 patients from clinical routine in whom ictal perfusion SPECT had been performed with stabilized 99mTc-HMPAO (n = 110) or 99mTc-ECD (n = 86). Lateralization and localization of the SOZ were obtained by the consensus of 2 independent readers based on visual inspection of the SPECT images.ResultsThe 99mTc-HMPAO group and the 99mTc-ECD group were well matched with respect to age, sex, age at first seizure, duration of disease, seizure frequency, history of previous brain surgery, and findings of presurgical MRI. The proportion of lateralizing ictal SPECT did not differ significantly between 99mTc-HMPAO and 99mTc-ECD (65.5% vs 72.1%, P = 0.36). Sensitivity of ictal perfusion SPECT (independent of the tracer) for correct localization of the SOZ in 62 patients with temporal lobe epilepsy and at least worthwhile improvement (Engel scale ≤ III) 12 months after temporal epilepsy surgery was 63%.ConclusionsThis study does not provide evidence to favor 99mTc-HMPAO or 99mTc-ECD for identification of the SOZ by ictal perfusion SPECT.

01 Sep 2021·Neurology and Clinical Neuroscience

Progression of cortical dysfunction in CSF1R‐related leukoencephalopathy detected using single‐photon emission computed tomography

Author: Yoshida, Kunihiro ; Minatani, Shinobu ; Hasegawa, Itsuki ; Takeda, Akitoshi ; Okamoto, Kosuke ; Hatsuta, Hiroyuki ; Yoshizaki, Takahito ; Miyazawa, Naotaka ; Sakaguchi, Hiroka ; Kondo, Yasufumi ; Mino, Toshikazu ; Abe, Takato ; Itoh, Yoshiaki

AbstractBackgroundHereditary diffuse leukoencephalopathy with spheroids (HDLS) is a rare autosomal dominant disease progressively affecting cognitive and motor functions, most often caused by mutations in the colony‐stimulating factor 1 receptor gene (CSF1R).AimTo elucidate the mechanism of disease progression, changes in white matter lesions and cortical cerebral blood flow (CBF) were evaluated in cases during various stages of the disease.MethodsAll patients were diagnosed with HDLS by confirming mutations in CSF1R. Regional CBF was evaluated using single‐photon emission computed tomography and was analyzed semiquantitatively.ResultsThree cases (2 males and 1 female, ages 51, 53, and 48 years on admission, disease duration from 1 to 8 years) were registered. All cases exhibited different CSF1R mutations and progressive frontal dysfunction. Scores of the Frontal Assessment Battery and time in the Trail Making Test worsened as the disease progressed, whereas the Mini‐Mental State Examination score remained relatively stable. MRI revealed progressive white matter lesions in the frontal lobe and atrophy of the anterior body of the corpus callosum. Regional CBF was low in the medial frontal cortex in the early case, and the area of hypoperfusion spread to the lateral frontal cortex and parietal cortex as the disease progressed. CBF was maintained in the basal ganglia, thalamus, and occipital lobes.ConclusionsHypoperfusion was initially observed in the medial frontal lobe and spread to the lateral frontal lobe and parietal lobe with disease progression. Spreading of accumulated abnormal proteins induced by mutation in CSF1R may be involved as a molecular mechanism of disease progression.

100 Deals associated with Technetium Tc-99M Bicisate Kit

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	V09A	-

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Central nervous system injury	United States	Lantheus Medical Imaging, Inc.	23 Nov 1994
Trauma, Nervous System	United States	Lantheus Medical Imaging, Inc.	23 Nov 1994
Brain Diseases	Japan	PDRadiopharma, Inc.	19 Jan 1994

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


EANM2021	Not Applicable	-	83	99m Tc-ECD (Manual method)	qwmvqvutvj(esywzqnwvt) = panidrhbck jxnjpvmlnm (pfhaawhmep )	Positive	24 Sep 2021
				99m Tc-ECD (Mathematical method)	qwmvqvutvj(esywzqnwvt) = cegdggsdiw jxnjpvmlnm (pfhaawhmep )
SNMMI2018	Not Applicable	Moya-Moya Disease	-	99m Tc-Ethyl cysteinate dimer (Pre-surgery)	mfykbwziig(jwndxbqwwn) = vvelbbmqvo zpbxjqkspm (mllvjtjnwl, 3.7) View more	-	23 May 2018
				99m Tc-Ethyl cysteinate dimer (Post-surgery)	mfykbwziig(jwndxbqwwn) = llfxtvdmlh zpbxjqkspm (mllvjtjnwl, 4.6) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Technetium Tc-99M Bicisate Kit

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation